Q-omics provides the consensus-scored FAM168B profile across patient tissues and cancer cell-line models. FAM168B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM168B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FAM168B RNA expression shows 20,364 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where FAM168B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM168B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM168B survival associations across molecular data types. FAM168B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM168B RNA expression–survival associations across cancer types. High FAM168B expression shows unfavorable associations in BLCA, ACC, CESC and LIHC, but favorable associations in KIRC and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM168B RNA expression.
This table summarizes FAM168B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM168B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM168B shows lower tumor expression in THCA, BLCA, KICH and BRCA and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher FAM168B RNA expression in tumor versus normal tissue (log2 FC = +0.758, t-test p < 0.001).
This table shows molecular features associated with FAM168B in patient tissues and cancer cell lines. In patient samples, FAM168B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM168B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
